MCID: LBL001
MIFTS: 52

Lobular Neoplasia

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia 11 14 71 75
Lobular Carcinoma in Situ of Breast 71 33
Lobular Carcinoma in Situ 11 31
Noninfiltrating Lobular Carcinoma Unspecified Site 33
Noninfiltrating Lobular Carcinoma of Breast 33
Lobular Carcinoma in Situ Unspecified Site 33
Non-Infiltrating Lobular Carcinoma 71
Lobular Intraepithelial Neoplasia 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3010
NCIt 49 C27939
ICD10 31 D05.0
ICD11 33 1313183227
UMLS 71 C0279563 C0334381 C0861352

Summaries for Lobular Neoplasia

Disease Ontology: 11 A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary: Lobular Neoplasia, also known as lobular carcinoma in situ of breast, is related to mammary paget's disease and breast duct papilloma. An important gene associated with Lobular Neoplasia is MIR520G (MicroRNA 520g), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Tamoxifen and Afimoxifene have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and smooth muscle, and related phenotypes are Increased cell migration and Increased cell death in HCT116 cells

Wikipedia: 75 Lobular neoplasia can refer... more...

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 412)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 30.5 PIP PGR ESR1 ERBB2
2 breast duct papilloma 30.3 PTEN PGR
3 microglandular adenosis 30.3 PIP PGR ESR1 ERBB2
4 intraductal papilloma 30.1 PGR KRT5 ESR1 ERBB2
5 comedo carcinoma 30.1 TP53 PGR KRT5 ESR1 ERBB2 BRCA2
6 gynecomastia 30.1 PGR ESR1 ERBB2 CYP19A1
7 benign breast phyllodes tumor 30.0 PGR ESR1
8 breast malignant phyllodes tumor 29.8 TP53 PGR KRT5 ESR1 ERBB2 EGFR
9 tubular adenocarcinoma 29.8 PGR ESR1 ERBB2 CTNNA1 CDH1
10 teratoma 29.8 TP53 PTEN ESR1 ERBB2 CDH1
11 breast disease 29.5 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
12 papilloma 29.4 TP53 PTEN KRT5 ERBB2 EGFR CDH1
13 small cell carcinoma 29.3 TP53 PTEN KRT5 EGFR
14 breast fibroadenoma 29.1 TP53 PGR KRT5 ESR1 ERBB2 EGFR
15 adenoid cystic carcinoma 28.9 TP53 PTEN PIK3CA PGR ERBB2 EGFR
16 rhabdomyosarcoma 28.8 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
17 bilateral breast cancer 28.8 TP53 PTEN PGR PALB2 ESR1 ERBB2
18 ductal carcinoma in situ 28.6 TP53 PTEN PIP PIK3CA PGR KRT5
19 mixed cell type cancer 28.5 TP53 PTEN PIK3CA PGR KRT5 ESR1
20 inherited cancer-predisposing syndrome 28.4 TP53 PTEN PALB2 EGFR CTNNA1 CDH1
21 bap1 tumor predisposition syndrome 28.4 TP53 PTEN PALB2 EGFR CTNNA1 CDH1
22 diffuse gastric cancer 28.3 TP53 PTEN PIK3CA PALB2 ERBB2 CTNND1
23 diffuse gastric and lobular breast cancer syndrome 28.3 TP53 PTEN PIK3CA PALB2 ERBB2 CTNND1
24 hypertrophy of breast 28.2 TP53 PTEN PIK3CA PGR KRT5 ESR1
25 esophageal cancer 28.2 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
26 breast ductal carcinoma 27.9 TP53 PTEN PIP PGR KRT5 ESR1
27 breast lobular carcinoma 27.8 TP53 PTEN PIP PIK3CA PGR PALB2
28 breast carcinoma in situ 27.7 TP53 PTEN PIP PIK3CA PGR MIR520G
29 lynch syndrome 27.6 TP53 PTEN PIK3CA PGR PALB2 ESR1
30 breast cancer 27.2 TP53 PTEN PIP PIK3CA PGR PALB2
31 uterine corpus adenosarcoma 10.4 PGR ESR1
32 adult cystic nephroma 10.4 PGR ESR1
33 vagina leiomyosarcoma 10.4 PGR ESR1
34 vulvar benign neoplasm 10.4 PGR ESR1
35 her2-receptor negative breast cancer 10.4 PGR ERBB2
36 progesterone resistance 10.4 PGR ESR1
37 hereditary site-specific ovarian cancer syndrome 10.4 BRCA2 BRCA1
38 ovary transitional cell carcinoma 10.4 BRCA2 BRCA1
39 cancerophobia 10.3 BRCA2 BRCA1
40 euryblepharon 10.3 CTNND1 CDH1
41 nosophobia 10.3 BRCA2 BRCA1
42 nipple carcinoma 10.3 PGR ESR1 ERBB2
43 breast mucinous cystadenocarcinoma 10.3 PGR ESR1 ERBB2
44 breast fibroadenosis 10.3 PGR ESR1 ERBB2
45 bulbospinal polio 10.3 PGR ESR1 ERBB2
46 spinal polio 10.3 PGR ESR1 ERBB2
47 glycogen-rich clear cell breast carcinoma 10.3 PGR ESR1 ERBB2
48 breast cystic hypersecretory carcinoma 10.3 PGR ESR1 ERBB2
49 breast-ovarian cancer, familial 2 10.3 BRCA2 BRCA1
50 intravenous leiomyomatosis 10.3 PGR ESR1

Graphical network of the top 20 diseases related to Lobular Neoplasia:



Diseases related to Lobular Neoplasia

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell migration GR00055-A-1 9.76 CTNNA1 CTNND1
2 Increased cell migration GR00055-A-3 9.76 CTNNA1 CTNND1
3 Increased cell death in HCT116 cells GR00103-A-0 8.96 CASK PIK3CA
4 Decreased viability in pancreas lineage GR00235-A 8.62 PGR TP53

MGI Mouse Phenotypes related to Lobular Neoplasia:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
2 neoplasm MP:0002006 10.41 BRCA1 BRCA2 CDH1 CTNNA1 CTNND1 EGFR
3 nervous system MP:0003631 10.4 BRCA1 BRCA2 CASK CTNNA1 CTNND1 CYP19A1
4 homeostasis/metabolism MP:0005376 10.38 BRCA1 BRCA2 CD2BP2 CDH1 CT45A10 CYP19A1
5 endocrine/exocrine gland MP:0005379 10.36 BRCA1 BRCA2 CDH1 CTNNA1 CTNND1 CYP19A1
6 cellular MP:0005384 10.36 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
7 limbs/digits/tail MP:0005371 10.34 BRCA1 BRCA2 CASK CTNNA1 EGFR ERBB2
8 digestive/alimentary MP:0005381 10.32 BRCA1 BRCA2 CASK CDH1 CTNND1 CYP19A1
9 embryo MP:0005380 10.31 BRCA1 BRCA2 CD2BP2 CDH1 CTNNA1 EGFR
10 normal MP:0002873 10.29 BRCA1 BRCA2 CDH1 CYP19A1 EGFR ERBB2
11 muscle MP:0005369 10.27 BRCA1 CTNNA1 CYP19A1 EGFR ERBB2 ESR1
12 cardiovascular system MP:0005385 10.25 BRCA1 CD2BP2 CDH1 CTNNA1 CYP19A1 EGFR
13 renal/urinary system MP:0005367 10.18 BRCA1 CD2BP2 CTNND1 CYP19A1 EGFR ESR1
14 immune system MP:0005387 10.18 BRCA1 BRCA2 CD2BP2 CDH1 CYP19A1 EGFR
15 adipose tissue MP:0005375 10.09 BRCA1 CYP19A1 EGFR ESR1 PIK3CA PTEN
16 pigmentation MP:0001186 10.08 BRCA1 CTNNA1 CYP19A1 EGFR PTEN TP53
17 reproductive system MP:0005389 10.07 BRCA1 BRCA2 CASK CDH1 CYP19A1 EGFR
18 craniofacial MP:0005382 10 CASK CTNNA1 CTNND1 EGFR ERBB2 KRT5
19 skeleton MP:0005390 9.93 BRCA1 BRCA2 CASK CTNNA1 CYP19A1 EGFR
20 respiratory system MP:0005388 9.92 BRCA1 CASK CTNND1 EGFR ERBB2 ESR1
21 mortality/aging MP:0010768 9.86 BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
22 integument MP:0010771 9.53 BRCA1 BRCA2 CASK CDH1 CTNNA1 CTNND1

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 2, Phase 3 10540-29-1, 54965-24-1 2733526
2
Afimoxifene Investigational Phase 2, Phase 3 68392-35-8 63062
3 Antineoplastic Agents, Hormonal Phase 2, Phase 3
4 Estrogens Phase 2, Phase 3
5 Estrogen Receptor Modulators Phase 2, Phase 3
6 Estrogen Receptor Antagonists Phase 2, Phase 3
7 Estrogen Antagonists Phase 2, Phase 3
8 Hormones Phase 2, Phase 3
9 Hormone Antagonists Phase 2, Phase 3
10 Selective Estrogen Receptor Modulators Phase 2, Phase 3
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
12
Epirubicin Approved Phase 2 56420-45-2 41867
13
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
14
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
15
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
16
Trastuzumab Approved, Investigational Phase 2 180288-69-1
17
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
18
Ethanol Approved Phase 2 64-17-5 702
19
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
20 Anti-Bacterial Agents Phase 2
21 Alkylating Agents Phase 2
22 Antirheumatic Agents Phase 2
23 Antineoplastic Agents, Alkylating Phase 2
24 Antimitotic Agents Phase 2
25 Angiogenesis Inhibitors Phase 2
26 Antimetabolites Phase 2
27 Tubulin Modulators Phase 2
28 Antibiotics, Antitubercular Phase 2
29 Antineoplastic Agents, Immunological Phase 2
30 Immunosuppressive Agents Phase 2
31 Immunologic Factors Phase 2
32 Narcotic Antagonists Phase 2
33 Narcotics Phase 2
34
Pasireotide Approved Phase 1 396091-73-9 56841596 9941444
35
Bexarotene Approved, Investigational Phase 1 153559-49-0 82146
36
Zinc cation Approved, Experimental, Investigational 7440-66-6, 23713-49-7 32051
37
Iodine Approved, Investigational 7553-56-2 807

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ Suspended NCT04570956 Phase 2, Phase 3 Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
2 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
3 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
4 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
5 A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer Active, not recruiting NCT03391388 Phase 2
6 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Terminated NCT02137252 Phase 2 Naltrexone;Sugar Pill
7 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial Completed NCT01372644 Phase 1 SOM 230 / Pasireotide
8 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery Active, not recruiting NCT03317405 Phase 1 Endoxifen Hydrochloride
9 A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer Active, not recruiting NCT03323658 Phase 1 Bexarotene
10 GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope Unknown status NCT00536718
11 The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy Completed NCT00146536
12 Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study Completed NCT01841749
13 Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ Completed NCT00620087
14 Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ Completed NCT00581750
15 Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer Recruiting NCT05086705
16 Improving Well-Being for Individuals With Persistent Pain After Surgery for Breast Cancer, Lobular Carcinoma in Situ, or Ductal Carcinoma in Situ: A Randomized Clinical Trial That Compares Three Behavioral Intervention Strategies and Examines Psychological Factors as Drivers of the Continuing Burden of Persistent Pain Recruiting NCT04225585
17 Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) Recruiting NCT04496739
18 Energy Balance and Breast Cancer Aspects-II Study Active, not recruiting NCT02240836
19 Efficacy, Safety, Cosmesis and Patient Satisfaction With Vacuum-Assisted Percutaneous Excision (VAPE) Compared With Standard Surgical Excision (X) of Non-malignant, Borderline or High-risk Breast Lesions: A Randomized Controlled Trial Not yet recruiting NCT03868475
20 Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute Not yet recruiting NCT05178498

Search NIH Clinical Center for Lobular Neoplasia

Genetic Tests for Lobular Neoplasia

Anatomical Context for Lobular Neoplasia

Organs/tissues related to Lobular Neoplasia:

MalaCards : Breast, Lymph Node, Smooth Muscle, Testis, Prostate, Colon, Lung

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 1241)
# Title Authors PMID Year
1
Lobular Neoplasia. 62
36335930 2022
2
High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. 62
35654997 2022
3
Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial. 62
36152791 2022
4
Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. 62
35771367 2022
5
Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade. 62
34942684 2022
6
The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions. 62
35951136 2022
7
Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR). 62
35869801 2022
8
ASO Author Reflections: Is Surgical Excision Necessary in Lobular Neoplasia with Synchronous Breast Carcinoma? 62
35818020 2022
9
ASO Visual Abstract: Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma. 62
35857198 2022
10
Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma. 62
35802213 2022
11
Value of Long-term Follow-up in Surgically Excised Lesions of Uncertain Malignant Potential in the Breast - Is 5 Years Necessary? 62
35732544 2022
12
Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. 62
35477749 2022
13
Management of breast complaints and high-risk lesions. 62
35570155 2022
14
Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis. 62
36171529 2022
15
Fine-needle aspiration of intramammary lymph nodes: a clinical, radiographic, and cytologic review. 62
36270911 2022
16
Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS. 62
35595928 2022
17
Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses. 62
35666367 2022
18
The positive predictive value of vacuum assisted biopsy (VAB) in predicting final histological diagnosis for breast lesions of uncertain malignancy (B3 lesions): A systematic review & meta-analysis. 62
35491362 2022
19
Upgrade Rates of Pure, Radiology-Pathology Concordant Lobular Neoplasia Diagnosed on Breast Core Needle Biopsy: Is Surgical Excision Warranted? 62
34702673 2022
20
Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. 62
35488092 2022
21
Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report. 62
35741268 2022
22
Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools. 62
35412592 2022
23
Lobular Carcinoma In Situ Incidentally Detected by Dual-Energy Computed Tomography 62
35466660 2022
24
Screening MRI in Women at Intermediate Breast Cancer Risk: An Update of the Recent Literature. 62
35783682 2022
25
The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS. 62
35567633 2022
26
Effective Surveillance of High-Risk Women. 62
34429241 2022
27
Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy. 62
35347040 2022
28
Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast. 62
35702498 2022
29
Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution. 62
35702494 2022
30
Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. 62
34554341 2022
31
Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. 62
34671879 2022
32
[Variants of breast lobular neoplasia: differential diagnosis and new molecular insight]. 62
35152642 2022
33
Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions. 62
34286593 2022
34
Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer. 62
35283633 2022
35
Multimodal Imaging of Target Detection Algorithm under Artificial Intelligence in the Diagnosis of Early Breast Cancer. 62
35047160 2022
36
Risk management recommendations and patient acceptance vary with high-risk breast lesions. 62
34325908 2022
37
Papillary lesions of the breast. 62
34734332 2022
38
Apocrine lesions of the breast. 62
34537861 2022
39
Early onset, delayed diagnosis and laterality of breast carcinoma: Evidence from a tertiary care hospital. 62
35910817 2022
40
Histiocytoid variant of invasive lobular breast carcinoma. A case report and literature review. 62
34868577 2021
41
Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. 62
34117603 2021
42
Is there an increasing trend of risk-reducing prophylactic mastectomy procedure in preventing breast cancer among women? 62
35677477 2021
43
[Updated WHO classification of tumors of the breast]. 62
34751805 2021
44
Lobular neoplasia detected at MRI-guided biopsy: imaging findings and outcomes. 62
33838434 2021
45
Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis. 62
34428722 2021
46
Photodynamic Therapy Induced Cell Death Mechanisms in Breast Cancer. 62
34638847 2021
47
Role of breast MRI in predicting histologic upgrade risks in high-risk breast lesions: A review. 62
34303150 2021
48
Comparison of the Imaging Features of Lobular Carcinoma In Situ and Invasive Lobular Carcinoma of the Breast. 62
36238391 2021
49
Impact of lobular carcinoma in situ on local recurrence in breast cancer treated with breast conservation therapy: a systematic review and meta-analysis. 62
33634956 2021
50
Kuwait National Mammography Screening Program: outcomes of 5 years of screening in Kuwaiti women. 62
34618610 2021

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

8 (show top 50) (show all 75)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87752998 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1676G>A p.S559N 16:68819390-68819390 10
2 COSM107640435 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.893C>A p.A298D 16:68811744-68811744 10
3 COSM145160856 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.770A>G p.D257G 16:68810279-68810279 10
4 COSM142974226 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.763C>T p.Q255* 16:68810272-68810272 10
5 COSM144547163 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.734C>T p.P245L 16:68810243-68810243 10
6 COSM145165659 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1866-4524G>A p.? 16:68829679-68829679 10
7 COSM144546942 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.274C>T p.H92Y 16:68801780-68801780 10
8 COSM107640594 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2138G>A p.R713K 16:68829679-68829679 10
9 COSM144547899 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.856G>A p.A286T 16:68811707-68811707 10
10 COSM144546390 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1595G>A p.W532* 16:68819309-68819309 10
11 COSM145153147 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.763C>T p.Q255* 16:68810272-68810272 10
12 COSM142988181 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.893C>A p.A298D 16:68811744-68811744 10
13 COSM142988327 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2384G>A p.R795K 16:68829679-68829679 10
14 COSM145165703 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1866-5976C>T p.? 16:68828227-68828227 10
15 COSM87754517 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.274C>T p.H92Y 16:68801780-68801780 10
16 COSM107628859 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.763C>T p.Q255* 16:68810272-68810272 10
17 COSM142988364 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2281C>T p.P761S 16:68828227-68828227 10
18 COSM145153098 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.760G>T p.D254Y 16:68810269-68810269 10
19 COSM145165484 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.856G>A p.A286T 16:68811707-68811707 10
20 COSM144547285 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1854-789C>T p.? 16:68833402-68833402 10
21 COSM87755934 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.893C>A p.A298D 16:68811744-68811744 10
22 COSM144548109 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1853+1673C>T p.? 16:68828227-68828227 10
23 COSM142986905 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.922G>A p.D308N 16:68811773-68811773 10
24 COSM144545407 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1676G>A p.S559N 16:68819390-68819390 10
25 COSM142986026 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1739G>A p.S580N 16:68819390-68819390 10
26 COSM145164442 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.274C>T p.H92Y 16:68801780-68801780 10
27 COSM144531682 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.763C>T p.Q255* 16:68810272-68810272 10
28 COSM144541605 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.770A>G p.D257G 16:68810279-68810279 10
29 COSM142983154 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.770A>G p.D257G 16:68810279-68810279 10
30 COSM87740032 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.760G>T p.D254Y 16:68810269-68810269 10
31 COSM87754742 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.734C>T p.P245L 16:68810243-68810243 10
32 COSM107640429 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.856G>A p.A286T 16:68811707-68811707 10
33 COSM144548251 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1830+1468G>A p.? 16:68823587-68823587 10
34 COSM107639825 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2369C>T p.S790L 16:68833402-68833402 10
35 COSM87754074 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1595G>A p.W532* 16:68819309-68819309 10
36 COSM142988178 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.856G>A p.A286T 16:68811707-68811707 10
37 COSM87754888 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2552C>T p.S851L 16:68833402-68833402 10
38 COSM144531632 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.760G>T p.D254Y 16:68810269-68810269 10
39 COSM144546606 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.922G>A p.D308N 16:68811773-68811773 10
40 COSM107639170 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.922G>A p.D308N 16:68811773-68811773 10
41 COSM145165488 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.893C>A p.A298D 16:68811744-68811744 10
42 COSM107640262 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1183G>A p.V395M 16:68815560-68815560 10
43 COSM87756131 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2321G>A p.R774K 16:68829679-68829679 10
44 COSM87749984 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.770A>G p.D257G 16:68810279-68810279 10
45 COSM142974180 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.760G>T p.D254Y 16:68810269-68810269 10
46 COSM107638085 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1493G>A p.S498N 16:68819390-68819390 10
47 COSM107640734 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.1942G>A p.A648T 16:68823587-68823587 10
48 COSM107639473 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.274C>T p.H92Y 16:68801780-68801780 10
49 COSM144547907 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.893C>A p.A298D 16:68811744-68811744 10
50 COSM142988493 CDH1 breast,NS,carcinoma in situ,lobular carcinoma in situ c.2188G>A p.A730T 16:68823587-68823587 10

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TP53 PTEN PIP ESR1 ERBB2 EGFR
2 13.76 TP53 PTEN PIK3CA PGR ESR1 ERBB2
3
Show member pathways
13.75 TP53 PTEN PIK3CA PALB2 ESR1 ERBB2
4
Show member pathways
13.29 PTEN PIP ERBB2 EGFR CTNND1 CTNNA1
5
Show member pathways
13.06 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
6 12.83 CTNNA1 CTNND1 EGFR ERBB2 ESR1 PGR
7
Show member pathways
12.68 EGFR ERBB2 ESR1 PIK3CA PTEN
8
Show member pathways
12.68 PIK3CA KRT5 CTNND1 CTNNA1 CDH1 CASK
9 12.59 TP53 PTEN PIK3CA EGFR CTNNA1 CDH1
10
Show member pathways
12.49 TP53 PIK3CA ERBB2 EGFR CDH1
11
Show member pathways
12.48 TP53 PTEN PIK3CA ERBB2 EGFR CTNNA1
12
Show member pathways
12.43 TP53 PIK3CA ERBB2 EGFR
13
Show member pathways
12.43 TP53 PTEN PIK3CA ESR1 ERBB2 CDH1
14
Show member pathways
12.38 PIK3CA ERBB2 EGFR CTNNA1 CDH1
15
Show member pathways
12.32 PIK3CA ESR1 ERBB2 EGFR
16 12.28 PTEN PIK3CA ERBB2 EGFR
17
Show member pathways
12.21 TP53 PTEN PIK3CA ERBB2 EGFR
18
Show member pathways
12.13 PTEN PIK3CA ERBB2 EGFR
19 12.09 EGFR ERBB2 PTEN TP53
20
Show member pathways
12.07 PIK3CA PGR ESR1 ERBB2 EGFR
21
Show member pathways
12.04 TP53 PTEN PIK3CA PGR ESR1 ERBB2
22
Show member pathways
12.03 TP53 PIK3CA ERBB2 EGFR
23
Show member pathways
11.97 PTEN PIK3CA ERBB2 EGFR
24 11.92 TP53 PTEN PIK3CA ERBB2
25
Show member pathways
11.89 TP53 BRCA2 BRCA1
26 11.87 TP53 PTEN PIK3CA
27
Show member pathways
11.84 ESR1 ERBB2 EGFR
28 11.81 TP53 PALB2 BRCA2 BRCA1
29
Show member pathways
11.8 TP53 BRCA2 BRCA1
30 11.75 TP53 PTEN ESR1
31 11.73 PIK3CA CTNNA1 CDH1
32 11.71 TP53 PTEN ESR1
33 11.68 BRCA1 ESR1 PGR
34 11.63 TP53 PTEN PIK3CA ERBB2 EGFR
35
Show member pathways
11.62 TP53 PTEN PIK3CA
36 11.59 PIK3CA CTNND1 CDH1
37 11.54 EGFR CTNND1 CTNNA1 CDH1
38 11.52 CTNND1 CTNNA1 CDH1
39 11.51 BRCA1 ERBB2 PIK3CA PTEN TP53
40 11.44 CTNND1 CTNNA1 CDH1
41 11.43 TP53 PTEN ESR1
42 11.43 CDH1 CTNNA1 CTNND1 EGFR
43 11.41 TP53 PTEN BRCA1
44 11.4 TP53 ERBB2 EGFR CDH1
45 11.4 TP53 PTEN ESR1 EGFR CYP19A1 CDH1
46
Show member pathways
11.36 PIK3CA CTNND1 CTNNA1 CDH1
47 11.33 PIK3CA ERBB2 EGFR CDH1
48 11.29 PIK3CA CTNND1 CTNNA1
49 11.24 CDH1 CTNNA1 PIK3CA
50 11.21 PGR ESR1 ERBB2 EGFR

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 9.46 BRCA2 BRCA1
2 catenin complex GO:0016342 9.43 CTNND1 CTNNA1 CDH1
3 DNA repair complex GO:1990391 9.1 PALB2 BRCA2 BRCA1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.1 TP53 PTEN PALB2 ERBB2 EGFR CTNNA1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.8 PTEN PIK3CA ERBB2
3 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.46 TP53 ESR1
4 chordate embryonic development GO:0043009 9.43 BRCA2 BRCA1
5 cellular response to ionizing radiation GO:0071479 9.43 TP53 BRCA2 BRCA1
6 positive regulation of miRNA maturation GO:1903800 9.37 TP53 EGFR
7 cellular response to indole-3-methanol GO:0071681 9.1 CTNNA1 CDH1 BRCA1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.93 TP53 PTEN PGR ESR1 EGFR BRCA1
2 identical protein binding GO:0042802 9.7 BRCA1 BRCA2 CDH1 CT45A10 CTNNA1 EGFR
3 beta-catenin binding GO:0008013 9.56 ESR1 CTNND1 CTNNA1 CDH1

Sources for Lobular Neoplasia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....